Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Acutaas Chemicals
Mid Cap•879 Employees•IPO 2021
Current Price
₹2187.70
-5.3 (-0.24%)Updated
Today's Range
2145
₹2187.70
2200.1
52 Week Range
52W Low₹1059.00
52W High₹2297.30
₹2187.70
Downside106.58%
Upside5.01%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹16,983.76 Cr
Market Cap
Total market value of companyP/E Ratio
59.18
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
7.63
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹34.79
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
9.89%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
19.90%
ROCE
Return on Capital Employed. >15% is goodNet Margin
24.29%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
21.31%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
33.68%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
24.10%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
93.50%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.01
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹159.97
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
32.70%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Outstanding quarterly profit growth of 93.50% demonstrates strong operational efficiency.
- •Robust quarterly sales growth of 24.10% indicates increasing market penetration.
Weaknesses
5 points- •High P/E ratio of 61.49 suggests potential overvaluation compared to peers.
- •Decreasing promoter holding from 41.05% to 32.66% may signal insider concerns.
Opportunities
5 points- •Operating in stable Pharmaceuticals industry offers long-term growth potential.
- •Strong quarterly growth provides opportunity to capture larger market share.
Threats
5 points- •Highly competitive Pharmaceuticals industry poses threat to market share.
- •Stringent and evolving regulations can impact product approvals and costs.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
RAM MOHAN LOKHANDE | 31 Dec 2024 | 06 Jan 2025 | 1,600 | 400 | ₹2,130 | SELL |
Chetankumar Chhaganlal Vaghasia | 19 May 2025 | 20 May 2025 | 1.23 Cr | 13.49 L | ₹1,115 | SELL |
NARESHKUMAR RAMJIBHAI PATEL | 19 May 2025 | 20 May 2025 | 1.45 Cr | 13.49 L | ₹1,115 | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹2320.40 | +₹132.70 | +6.07% |
| R3 | ₹2265.30 | +₹77.60 | +3.55% |
| R2 | ₹2232.70 | +₹45.00 | +2.06% |
| R1 | ₹2210.20 | +₹22.50 | +1.03% |
| PIVOT | ₹2177.60 | -10.10 | -0.46% |
| CURRENT | ₹2187.70 | - | - |
| S1 | ₹2044.90 | -₹142.80 | -6.53% |
| S2 | ₹2100.00 | -₹87.70 | -4.01% |
| S3 | ₹2122.50 | -₹65.20 | -2.98% |
| S4 | ₹2155.10 | -₹32.60 | -1.49% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-8.9% vs avg
3.03L
(11 Mar 2026)Delivery %+3.9% vs avg
53.4%
(11 Mar 2026)Avg Volume (20D)20-day average
3.33L
(11 Feb - 11 Mar)Avg Delivery %Trend ↓
49.6%
(11 Feb - 11 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Astrazeneca Pharma India Ltd
60.10 %
Highest Dividend Yield
Pfizer Ltd
3.28 %
Peer Comparison
| Company Name |
|---|
 Alivus Life Sciences Ltd |
 Alembic Pharmaceuticals Ltd |
 Astrazeneca Pharma India Ltd |
 Blue Jet Healthcare Ltd |
 Caplin Point Laboratories Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 ERIS Lifesciences Ltd |
 Granules India Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 |
 Sanofi India Ltd |
 Sanofi Consumer Healthcare India Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Acutaas Chemicals Ltd
Acutaas Chemicals Limited is a prominent player in the pharmaceutical and specialty chemicals industry, headquartered in Surat, India. The company's core business revolves around the research, development, manufacturing, and global distribution of pharmaceutical intermediates. These intermediates serve as crucial building blocks for the synthesis of various active pharmaceutical ingredients (APIs).
Acutaas's pharmaceutical intermediate portfolio caters to a broad spectrum of therapeutic areas. Their products are integral components in the production of APIs for medications targeting conditions such as retroviral infections, inflammatory diseases, psychotic disorders, cancer, Parkinson's disease, depression, and blood clotting disorders. This highlights their significant contribution to the development and manufacture of essential medicines.
Beyond pharmaceutical applications, Acutaas Chemicals Limited also produces a range of specialty chemicals. These find applications in diverse sectors including agrochemicals (pesticides and herbicides), cosmetics, and polymers (plastics and resins). Specifically, they manufacture and supply parabens (used as preservatives), salicylic acid (with applications in various industries), and other custom-synthesized chemicals for various industrial uses. This diversification broadens their customer base and revenue streams.
The company's international reach is notable, with a significant portion of its production exported globally. This demonstrates their capability to meet international quality standards and successfully compete in a highly competitive global market. The company's history, dating back to its founding in 2004 as Ami Organics Limited and rebranding in May 2025, suggests a track record of growth and adaptation within the industry.
In summary, Acutaas Chemicals Limited operates as a vertically integrated chemical company. Their business model encompasses the entire value chain, from research and development to the global marketing and sales of diverse chemical products. Their focus on pharmaceutical intermediates, coupled with their expertise in specialty chemicals, positions them strategically within the rapidly evolving global chemical landscape.
COMPANY FACTS - ACUTAAS
Registered Address
440/4, 5, 6, 8206-B,, 478, 479 & 494, 495,Road No : 82/A & 82/C, G.I.D.C,Sachin,
Surat
GUJARAT
IN
Tel: 917573015366
Website:https://acutaas.com/index.php
Investor Relations:http://www.amiorganics.com/investors.html
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 879
IPO Date: 14/09/2021
MANAGEMENT - ACUTAAS
Mr. Nareshkumar Patel
Executive Chairman of the Board and Managing Director
Mr. Bhavin Shah
Chief Financial Officer
Mr. Chetansinh Parmar
Chief Information Security Officer
Mrs. Ekta Srivastava
Company Secretary and Compliance Officer
Mr. Ram Lokhande
Whole Time Director
Mr. Virendra Mishra
Whole Time Director
Mr. Chetankumar Vaghasia
Whole Time Director
Dr. Anita Bandyopadhyay
Non-Executive Independent Director
Mr. Hetal Gandhi
Non-Executive Independent Director
Mrs. Richa Goyal
Non-Executive Independent Director
Mr. Girikrishna Maniar
Non-Executive Independent Director
Investor Questions Answered
Acutaas Chemicals Ltd (ACUTAAS) Stock FAQs
Get answers to the most common questions about Acutaas Chemicals Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Acutaas Chemicals Ltd (ACUTAAS) is ₹2,187.7. Today, the stock has declined by ₹5.30 (0.24%), trading in a range of ₹2,145 to ₹2,200.1. The stock opened at ₹2,198.3 with a trading volume of 4,57,626 shares.
Acutaas Chemicals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹16,983.76 crores, P/E ratio of 59.18, ROE of 9.89%, and ROCE of 19.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Acutaas Chemicals Ltd (ACUTAAS) is ₹2,297.3, while the 52-week low is ₹1,059. Currently trading at ₹2,187.7, the stock is 91.1% away from its 52-week low and 4.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Acutaas Chemicals Ltd stock at ₹2,187.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 59.18 and P/B ratio of N/A. Today's performance shows a loss of 0.24%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Acutaas Chemicals Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹2,187.7, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Acutaas Chemicals Ltd's key financial metrics include: P/E Ratio: 59.18, P/B Ratio: N/A, ROE: 9.89%, ROCE: 19.90%, Dividend Yield: 0.00%, EPS: ₹34.79, Book Value: ₹159.97, Debt-to-Equity: 0.01, and Current Ratio: N/A. The company's market cap stands at ₹16,983.76 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Acutaas Chemicals Ltd stock opened at ₹2,198.3 and is currently trading at ₹2,187.7, showing a decline of ₹5.30 (0.24%). The intraday high is ₹2,200.1 and low is ₹2,145. The trading volume stands at 4,57,626 shares, indicating moderate market participation today.
Acutaas Chemicals Ltd has a Price-to-Earnings (P/E) ratio of 59.18, which means investors are willing to pay ₹59.18 for every ₹1 of earnings. With an EPS of ₹34.79, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Acutaas Chemicals Ltd has a market capitalization of ₹16,983.76 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹2,187.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Acutaas Chemicals Ltd has a book value of ₹159.97 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹2,187.7, which is 1267.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Acutaas Chemicals Ltd has a Return on Equity (ROE) of 9.89% and Return on Capital Employed (ROCE) of 19.90%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Acutaas Chemicals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Acutaas Chemicals Ltd has a debt-to-equity ratio of 0.01, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Acutaas Chemicals Ltd has an Earnings Per Share (EPS) of ₹34.79, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹2,187.7 and P/E ratio of 59.18, investors are paying 59.18 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Acutaas Chemicals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Acutaas Chemicals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Acutaas Chemicals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (59.18), ROE (9.89%), debt-to-equity (0.01), and growth rates. 2) Technical Analysis - Check 52-week range (₹1059.00 - ₹2297.30), moving averages, and chart patterns. 3) Valuation - Compare current price (₹2187.70) with book value (₹159.97) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Acutaas Chemicals Ltd share is ₹5.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹2,187.7 is 43654x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Acutaas Chemicals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1059.00 - ₹2297.30). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.01 indicates leverage. 4) Liquidity Risk - Based on trading volume of 4,57,626 shares. 5) Valuation Risk - P/E of 59.18 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Acutaas Chemicals Ltd operates in the industry with key metrics: P/E ratio of 59.18, ROE of 9.89%, market cap of ₹16,983.76 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.01), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Acutaas Chemicals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹2,187.7, with a 52-week range of ₹1059.00 to ₹2297.30. Based on fundamentals like P/E (59.18), ROE (9.89%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Acutaas Chemicals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹2187.70. 2) Fundamental Deterioration - Declining ROE (currently 9.89%), increasing debt (D/E: 0.01), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Acutaas Chemicals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu